Channing Smith, MD
Family Medicine · Jackson, MINPI 1699795781
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,512 of the $21,504 with a category attached, or 81.4%. It is spread thinly across 60 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $6,327 and has fallen 57.8% since, to $2,670 in 2025. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,146 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$4K
- Novo Nordisk$3K
- Amgen$2K
- Pfizer$2K
- AstraZeneca$1K
- AbbVie$1K
- plus $9K from 54 others
What the payments were for
- Consulting fees$2,53012%
- Travel & lodging$1,3896%
- Food & beverage$17,51281%
- Education$120%
- Other$620%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,504 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 92 | $116,968 |
| OzempicSemaglutide | 72 | $116,425 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 121 | $101,063 |
| XareltoRivaroxaban | 59 | $85,862 |
| RybelsusSemaglutide | 35 | $65,222 |
| TrulicityDulaglutide | 49 | $62,020 |
| JardianceEmpagliflozin | 50 | $61,612 |
| MounjaroTirzepatide | 33 | $42,034 |
| MyrbetriqMirabegron | 29 | $24,423 |
| Repatha SureclickEvolocumab | 23 | $22,264 |
| FarxigaDapagliflozin Propanediol | 22 | $20,756 |
| JanuviaSitagliptin Phosphate | 14 | $19,887 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $17,031 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 64 | $14,308 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $8,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,593 | $181,647107 claims |
| GSKTrelegy Ellipta, Shingrix, Arexvy | $757 | $121,984206 claims |
| PfizerEliquis | $1,519 | $116,96892 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $816 | $104,05482 claims |
| Johnson & JohnsonXarelto | $689 | $85,86259 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $590 | $69,18665 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,306 | $41,09353 claims |
| Astellas Pharma US IncMyrbetriq | $4,385 | $24,42329 claims |
| MerckJanuvia | $527 | $19,88714 claims |
| AbbVieLinzess | $1,287 | $6,29812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Jackson
- Matt RosenbergJackson$550K
- Stephen ArntzJackson$20K
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.